Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $98.59 USD
Change Today -0.35 / -0.35%
Volume 21.1K
CBPO On Other Exchanges
Symbol
Exchange
Frankfurt
As of 8:10 PM 04/24/15 All times are local (Market data is delayed by at least 15 minutes).

china biologic products inc (CBPO) Snapshot

Open
$99.18
Previous Close
$98.94
Day High
$99.66
Day Low
$97.77
52 Week High
04/16/15 - $102.80
52 Week Low
05/8/14 - $33.49
Market Cap
2.4B
Average Volume 10 Days
128.6K
EPS TTM
$2.73
Shares Outstanding
24.8M
EX-Date
--
P/E TM
36.1x
Dividend
--
Dividend Yield
--
Current Stock Chart for CHINA BIOLOGIC PRODUCTS INC (CBPO)

Related News

No related news articles were found.

china biologic products inc (CBPO) Related Businessweek News

No Related Businessweek News Found

china biologic products inc (CBPO) Details

China Biologic Products, Inc. engages in the research, development, manufacture, and sale of human plasma-based biopharmaceutical products to hospitals and inoculation centers in the People's Republic of China. It offers human albumin for treating shock caused by blood loss trauma or burn; raised intracranial pressure caused by hydrocephalus or trauma; oedema or ascites caused by hepatocirrhosis and nephropathy; and neonatal hyperbilirubinemia, as well as for the prevention and treatment of low-density-lipoproteinemia. The company also offers human hepatitis B immunoglobulin for the prevention of measles and contagious hepatitis; human immunoglobulin and immunoglobulin for intravenous injection products for original and secondary immunoglobulin deficiency, and auto-immune deficiency diseases; and Thymopolypeptides injection for the treatment of original and secondary T-cell deficiency syndromes, auto-immune deficiency diseases, and cell immunity deficiency diseases, as well as assists in the treatment for tumors. In addition, it provides human rabies immunoglobulin primarily for passive immunity from bites or claws by rabies or other infected animals; human tetanus immunoglobulin for the prevention and therapy of tetanus; placenta polypeptide for the treatment of cell immunity deficiency diseases, viral infection, and leucopenia, as well as assists in postoperative healing; human coagulation factor VIII for treating coagulopathie; and human prothrombin complex concentrate for treating congenital and acquired clotting factor II, VII, IX, X deficiency, as well as excessive anticoagulant, vitamin K deficiency, etc. Further, the company is developing human hepatitis B immunoglobulin (PH4) for intravenous injection; human fibrinogen; immune globulin intravenous; human antithrombin III; and human cytomegalovirus immunoglobulin. It distributes its products directly or through distributors. The company is headquartered in Beijing, the People's Republic of China.

1,621 Employees
Last Reported Date: 03/4/15

china biologic products inc (CBPO) Top Compensated Officers

Executive Chairman, Chief Executive Officer a...
Total Annual Compensation: $878.7K
Chief Financial Officer and Principal Account...
Total Annual Compensation: $328.7K
Senior Corporate Vice President and Corporate...
Total Annual Compensation: $244.2K
Corporate Vice President
Total Annual Compensation: $265.5K
Corporate Vice President
Total Annual Compensation: $169.3K
Compensation as of Fiscal Year 2013.

china biologic products inc (CBPO) Key Developments

China Biologic Products Seeks Acquisitions

China Biologic Products, Inc. (NasdaqGS:CBPO) is seeking acquisitions. Ming Yang, Chief Financial Officer of China Biologic, said "If a right opportunity arises, the funding, the acquisition, it never will be a problem for us because we have a large untapped loan facility if we need it."

China Biologic Products, Inc. Announces Board Changes

China Biologic Products, Inc. announced that on March 2, 2015, Mr. Dai Feng resigned from the board of directors of the Company, effective from the same date. On the same date, the Board appointed Mr. Min Fang, as a director of the Company with immediate effect to fill the vacancy resulting from Mr. Fang's resignation from the Board. Mr. Fang has been a principal at Beijing Warburg Pincus Investment Consulting Company Limited Shanghai Branch since July 2011, and a core member of the China healthcare team. In addition to his role with the Company, Mr. Fang currently serves on the board of several private companies including, among others, EA Inc. and Beijing Amcare Women's and Children's Hospital Co. Ltd.

China Biologic Products, Inc. Reports Consolidated Earnings Results for the Fourth Quarter and Year Ended Dec. 31, 2014; Provides Earnings Guidance for the Year of 2015

China Biologic Products, Inc. reported consolidated earnings results for the fourth quarter and year ended Dec. 31, 2014. For the quarter, the company’s total sales increased by 36.2%, or 36.8% excluding the impact of foreign currency exchange rate changes, to $58.0 million from $42.6 million in the same quarter of 2013. Income from operations increased by 57.6% to $19.7 million from $12.5 million in the last quarter of 2013. Net income attributable to the company increased by 46.6% to $12.9 million from $8.8 million in the last quarter of 2013. Fully diluted net income per share was $0.48 in the fourth quarter of 2014 as compared to $0.32 in the fourth quarter of 2013. Non-GAAP adjusted net income attributable to the company was $14.7 million, representing a 53.1% increase from $9.6 million in the same quarter of 2013. Non-GAAP adjusted net income per share was $0.56, compared to $0.35 in the last quarter of 2013. For the year, the company reported sales of $243,251,658 compared to $203,356,856 a year ago. Income from operations was $111,158,913 compared to $86,932,518 a year ago. Earnings before income tax expense were $122,752,161 compared to $92,401,365 a year ago. Net income attributable to the company was $70,916,840 or $2.71 per diluted share compared to $54,601,551 or $1.96 per diluted share a year ago. Net cash provided by operating activities was $93,514,318 compared to $74,302,995 a year ago. Payment for property, plant and equipment was $17,194,201 compared to $20,492,159 a year ago. Payment for intangible assets and land use rights was $4,677,358 compared to $1,327,148 a year ago. Adjusted net income attributable to the company was $75,555,173 or $2.89 per diluted share compared to $58,974,178 or $2.12 per diluted share a year ago. Excluding the potential adverse impact of foreign currency, the company expects total sales for 2015 to be in the range of $287 million to $292 million, which represents growth of 18% to 20% over 2014, and full year non-GAAP adjusted net income attributable to the company for 2015 to be in the range of $95 million to $97 million, which represents growth of 26% to 28% over 2014. Taking into account the potential impact of foreign currency, the company expects sales and non-GAAP adjusted net income to be negatively impacted by approximately 4% to 5% by applying a current twelve-month forward exchange rate projection of RMB 6.41 = $1.00.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CBPO:US $98.59 USD -0.35

CBPO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Hualan Biological Engineering Inc CNY54.02 CNY +1.22
Jiangxi Boya Bio-Pharmaceutical Co Ltd CNY75.46 CNY 0.00
Shanghai RAAS Blood Products Co Ltd CNY63.47 CNY -0.56
View Industry Companies
 

Industry Analysis

CBPO

Industry Average

Valuation CBPO Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CHINA BIOLOGIC PRODUCTS INC, please visit www.chinabiologic.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.